Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

WEIGHT LOSS · ONCE WEEKLYPhase 3 TrialsPopular · Next-Gen GLP-1

Retatrutide

Triple Agonist · 10mg

Vial size

Status

Phase 3 Trials

Route

SubQ

Half-life

~6 days

Class

Triple agonist (investigational)

MechanismGLP-1 / GIP / Glucagon Triple Agonist

Cohort31 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$175 USD/vial

À-la-carte: $195 USD/vial · Save 10%

Vials per allocation

Member total (1×)$175

À-la-carte total$195

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Triple-receptor agonist adding glucagon pathway activation to GLP-1/GIP. Emerging profile for advanced metabolic cases under physician supervision.

Triple Agonist · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-M2

Metabolic Plus - Advanced Weight Loss

Popular · Next-Gen Metabolic

Retatrutide · Weight loss · once weekly

◆ Certificate of Analysis · Retatrutide

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-RTA-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

Lot · Retatrutide-2026-07-30

99.726%

Labeled

5 mg

Actual (HPLC)

5.16 mg

Method

HPLC + MS

Tested

Jul 30, 2026

Endotoxin

Heavy metals

As, Cd, Pb, Hg - not detected

Verify independently at janoshik.com/verificationPurity - code ERPESIN5JUHCEndotoxin - code 31WVLFB94WU5Heavy metals - code YXDMMMD4KRGB

◉

Clinical Overview

Retatrutide

Retatrutide is an investigational triple agonist of GLP-1, GIP, and glucagon receptors. Currently in late-stage clinical trials for obesity and metabolic disease.

Higher cohort weight reduction vs. Tirzepatide in early trials, but with a more complex side effect profile requiring careful patient selection.

✦

Triple-Receptor Action

GLP-1, GIP, and glucagon activation - investigational triple agonist.

❤

Energy Expenditure

Glucagon arm adds an energy-expenditure component (investigational).

◈

Appetite & Insulin

Appetite suppression and insulin sensitization via incretin pathways.

◈

Mechanism

How It Works

Triple-pathway activation: GLP-1 (insulin/satiety), GIP (insulin/lipolysis), and glucagon (energy expenditure). The glucagon component differentiates it from Tirzepatide and contributes to additional caloric burn.

⚐

Patient Education

Before & during use - what to know

Retatrutide is investigational. It is the most potent GLP-1-class agent yet studied (triple GLP-1 / GIP / glucagon receptor activation), with Phase 2 weight reduction reaching ~24.2% at 48 weeks in published data. The same potency that makes it effective also makes the safety, titration, and lifestyle context below non-optional. None of what follows is a dosing instruction - it is patient-education context to discuss with your physician.

↗TitrationThe Phase 3 ladder, and why Vivre often targets 9 mg, not 12 mg

The Eli Lilly TRIUMPH Phase 3 titration protocol is 2 mg → 4 mg → 6 mg → 9 mg → 12 mg, holding each dose for 4 weeks before escalating. Maintenance doses studied in Phase 3 are 4 mg, 9 mg, and 12 mg. The single most important finding for patient education: TRIUMPH-4 data shows the 9 mg dose produces nearly equivalent efficacy to 12 mg (26.4% vs 28.7% body weight loss at 68 weeks) with materially better tolerability. For most patients, 9 mg is the right target - not 12 mg. The 4 mg arm is studied as a post-titration maintenance dose for patients who have reached their goal and want to hold the result. **Sensitivity-adapted start option:** Phase 2 trials also validated 0.5 mg (Type 2 diabetes arm) and 1 mg (obesity arm) as fixed starting doses - both were well-tolerated with modest standalone effects. Vivre offers a slower start (0.5–1 mg weekly for 2–3 weeks before stepping to 2 mg) under physician supervision for first-time GLP-1 users, patients with known GI sensitivity, or anyone who has had bad experiences with semaglutide or tirzepatide. This is not the same as indefinite microdosing - the goal is improved tolerability through the 2 mg threshold, not staying below it permanently. Phase 3 discontinuation rates were 12–18% even on the slow standard titration, so the slower-start option meaningfully helps a real cohort of patients. The clinical principle remains "maximum tolerated dose, not maximum dose, is the target" - patients who cannot tolerate 2 mg even with the slower start may be better candidates for tirzepatide or semaglutide.

Vivre's default protocol targets 9 mg maintenance under physician supervision, not 12 mg. The Phase 3 evidence supports this as the right tolerability-efficacy trade-off for most patients. Sensitivity-adapted starts (0.5–1 mg) are available for first-time GLP-1 users on physician request.

♡Cardiovascular MonitoringResting heart rate elevation is expected

Retatrutide consistently elevates resting heart rate. Phase 3 TRIUMPH-4 reported a mean increase of approximately 5–10 BPM during active titration, easing over time as the body adapts. This is a known class effect of GLP-1 / GIP / glucagon agonists, more pronounced with retatrutide than with semaglutide or tirzepatide because the glucagon-receptor component drives additional energy expenditure. Track resting HR (a wearable is fine) at baseline and weekly through titration. Persistent resting HR above your individual baseline, palpitations, or any chest discomfort warrants pausing and contacting your physician immediately. A second Phase 3 finding worth knowing: approximately 20% of TRIUMPH-4 participants on the highest dose reported dysesthesia - skin sensitivity or tingling - which is one of the reasons Vivre defaults to 9 mg rather than 12 mg targets. Do not initiate without an honest cardiovascular history review with your physician.

Vivre recommends caution for patients with known arrhythmia, recent cardiac events, or untreated hypertension. In these cases, allocation is reviewed individually and a cardiologist should be part of the protocol.

◊Lifestyle FoundationThe drug is not the protocol - the protocol is the protocol

GLP-1 weight loss without lifestyle change rebounds. Published evidence on tirzepatide discontinuation shows ~50% weight regain within 12 months when no dietary or behavioural foundation is in place. The lifestyle context is not optional adjunct - it is the protocol. A sustainable result requires: a moderate caloric deficit (not extreme - the appetite suppression already produces a substantial deficit), **adequate protein (target 1.6–2.0 g/kg body weight daily during active weight loss to preserve lean mass; patients starting with very low baseline protein intake can begin at 1.25–1.5 g/kg as a floor and progress upward)**, micronutrient-dense food (the appetite suppression makes deficiencies easier to develop), resistance training at least 2× weekly (preserves lean mass while losing fat), and adequate sleep. Without these, the drug is an expensive temporary solution.

◇Digestion & HydrationGastric emptying slows - eat and drink accordingly

All GLP-1-class agents delay gastric emptying. Practical consequence: smaller meals, eaten slowly, with attention to early-satiety signals. Heavy or fatty meals can produce hours of discomfort. **A note on carbonated water:** despite community-practice mentions of carbonated water easing fullness, current clinical guidance points the opposite direction - trapped CO2 from carbonation amplifies bloating, distension, and reflux when gastric emptying is already delayed. Standard physician advice for GLP-1 patient management is to avoid carbonated beverages during titration and at higher doses. Still water, ginger tea, peppermint tea, or warm water are the better choices for nausea or early-fullness. **Hydration pattern:** sip throughout the day rather than gulping at meals - filling the stomach with fluid while gastric emptying is delayed amplifies fullness and nausea. Aim for steady fluid intake away from meals. **Electrolyte awareness:** sodium, potassium, and magnesium loss accelerates when appetite suppression reduces food intake. Persistent fatigue, dizziness, or muscle cramps during titration weeks often resolve with light electrolyte supplementation - discuss with your physician.

☉Practical Do's & Don'tsLifestyle patterns that user reports and physician practice converge on

The following is community-experience guidance triangulated with physician practice - not clinical-trial protocol, but consistent enough across thousands of self-reported user accounts that it is worth knowing. DO: Pin once weekly (split twice-weekly is mechanistically defensible based on retatrutide's 6-day half-life and peak-trough profile - some patients find it eases GI burden - but adds complexity; once-weekly remains the cleanest cadence). DO: Electrolytes daily, especially during active titration and weight loss - sodium, potassium, magnesium loss accelerates when appetite suppression reduces food intake. DO: Eat clean - protein-forward (chicken, fish, lean meat), vegetables, modest portions of clean carbs (white rice, potatoes, oats). The body is more sensitive to food quality than usual when gastric emptying is delayed. DO: Move - resistance training 2× weekly is the lean-mass-preservation anchor; daily walks help GI motility. DON'T: Spicy food on dosing day. Multiple user reports converge on this - the slowed gastric emptying amplifies what was already a strong stimulus. DON'T: Heavy or greasy meals around the dose window. Same reasoning. DON'T: Drink heavily - alcohol calories displace nutrient calories at a time when both are reduced; beer specifically fills the stomach and crowds out food. DON'T: Strict keto without medical supervision - the glucagon-receptor activation creates a theoretical ketoacidosis risk that has not been characterised in trial populations. If carb restriction is part of your protocol, blood ketone monitoring becomes mandatory. DON'T: Self-dose-adjust without consulting your physician - peptide calculator math errors are one of the most common reasons for unexpectedly severe early experiences.

This guidance is community-experience pattern, not RCT evidence. Individual response varies. Anything that worsens consistently - symptoms, mood, energy - is a physician conversation, not a self-titration adjustment.

❄Storage & StabilityVivre sizes vials to your titration window - not pharmaceutical-distribution convenience

Reconstituted peptides degrade over time. Industry-standard data for bacteriostatic-water reconstituted GLP-1-class peptides places usable potency at approximately 4 weeks refrigerated, with measurable degradation accumulating beyond that - aggregation, oxidation, and conformational drift (α-helix → random coil) are the relevant pathways. Once you mix the vial, every additional day in solution is degradation, even at proper refrigeration. Vivre sizes retatrutide vials at 10–20mg specifically to match a real titration or maintenance window of 2–4 weeks per vial, so the product you inject in week 3 is at near-peak potency rather than degraded by a long shelf life in solution. The trade-off is more frequent shipments and reconstitutions versus larger 30–50mg vials some research vendors sell - but those larger vials only work at peak potency for the first 2–3 weeks of a 4–6 week consumption window. Sizing matters for your dose-to-dose consistency, especially during active titration where you want every injection to deliver what it says.

Standard storage: keep lyophilized vials refrigerated 2–8°C (or room-temp short-term before reconstitution). After reconstitution, refrigerated 2–8°C only - never freeze, never expose to direct light, never leave at room temperature beyond brief warming for injection.

⊙CyclingVivre recommends 3 months on, 1 month off

Vivre recommends cycling retatrutide on a 3-months-on, 1-month-off cadence under physician supervision. The reasoning: (a) extended continuous GLP-1 / GIP / glucagon receptor activation may produce receptor downregulation or desensitization over time, and a planned washout helps preserve responsiveness; (b) the digestive-tract effects of prolonged gastric-emptying delay are not fully characterised over multi-year horizons - retatrutide is investigational and long-term GI safety data does not yet exist; (c) the off-month gives the body a recovery window, lets patients confirm lifestyle changes are sustaining benefit independent of the drug, and resets tolerance for the next on-cycle. Honest framing: this is not a clinical-trial-validated protocol - Phase 2 and Phase 3 trials run continuous dosing. Vivre's cycling recommendation is based on mechanistic reasoning and physician judgement, not RCT evidence. Patients with severe metabolic indications may have physician guidance to maintain continuous dosing instead.

The off-month is not a free pass - lifestyle foundation (diet, protein, resistance training) must continue. The cycling recommendation assumes those are in place.

◇Side-Effect ManagementNausea on a step-up is common - your physician manages it

Nausea or stomach upset is common when stepping up a dose. Your physician manages this directly - including adjusting your dose or, if appropriate, prescribing supportive medication. Vivre's approach is deliberately conservative: we start lower than the label and advance only when you are tolerating the current step. Don't manage significant side effects on your own - use your support channel. This is education, not a recommendation to take anything; dosing and any supportive medication are physician decisions.

The points above are educational context, not medical advice. Retatrutide is investigational and not FDA-approved. Vivre allocates retatrutide only with physician case review, informed consent that addresses the cardiovascular and titration risks above, and a documented lifestyle and monitoring plan.

Common Questions

What patients ask before their consultation

Should I microdose retatrutide? I have heard 0.5–1 mg works with fewer side effects.

The honest answer has two parts. First, the evidence: Eli Lilly's Phase 2 trials tested 0.5 mg (in the Type 2 diabetes arm) and 1 mg (in the obesity arm) as fixed doses. Both were well-tolerated; both produced modest weight loss - meaningfully less than the 4–12 mg therapeutic doses. So "microdosing" is a real clinical category, just one with smaller effects. Second, Vivre's position: a 0.5–1 mg sensitivity-adapted start under physician supervision is reasonable for first-time GLP-1 users, patients with known GI sensitivity, or anyone who has had bad experiences with semaglutide or tirzepatide. We support this when clinically appropriate. For patients whose goal is significant weight loss, the Phase 2 data on sub-2 mg fixed dosing shows the efficacy curve flattens substantially - so we would typically work with the patient to either continue titrating toward a therapeutic dose, or consider whether tirzepatide or semaglutide (which have larger tolerability margins at therapeutic doses) might be a better fit. The decision is collaborative and depends on the patient's tolerance, goals, and prior experience - not a fixed protocol.

Why does Vivre target 9 mg, not 12 mg?

Because TRIUMPH-4 Phase 3 data showed 9 mg produces ~26.4% body weight loss at 68 weeks versus 12 mg's ~28.7% - a 2.3 percentage point gap. Meanwhile the 12 mg arm reported approximately 20% dysesthesia (skin sensitivity/tingling) and materially higher GI burden. The trade-off is unfavourable for most patients. Where 12 mg is appropriate is severe metabolic disease, MASLD with high liver fat content, or patients who have plateaued at 9 mg and demonstrated good tolerability - a physician decision, not a default.

Can I split my weekly dose into twice-weekly injections?

Mechanistically yes, this is defensible. Retatrutide has a 6-day half-life with significant peak-trough variation at weekly dosing - plasma roughly doubles at the injection peak versus the pre-injection trough. GI side effects and heart-rate response track peak concentration, not weekly total. Splitting the dose halves the peak while keeping cumulative weekly exposure identical, which is why some patients find it eases GI burden. The trade-off is complexity and adherence - Phase 3 trials all ran once-weekly dosing and adherence declines as dosing frequency rises. Vivre's default is once-weekly; we will support twice-weekly split dosing when GI tolerability is the rate-limiting factor and the patient prefers the trade-off.

How does retatrutide affect what I should eat? Does it change how my body handles carbs?

Retatrutide meaningfully improves insulin sensitivity - the Phase 2a MASLD trial documented HOMA2-IR (the standard insulin-resistance index, computed from fasting insulin) reductions of up to 69.3% at 48 weeks versus placebo, with significant improvements at all doses ≥4 mg. The Phase 2 obesity trial (NEJM 2023) showed 72% of participants with prediabetes at baseline reverted to normoglycemia. Fasting insulin dropped up to 70.9% from baseline; serum C-peptide dropped up to 50.5%. Mechanistically: the GIP and GLP-1 components enhance glucose-stimulated insulin secretion and shift glucose disposal toward muscle, while the glucagon component increases basal energy expenditure. Combined, this means your body processes carbohydrates more efficiently while on therapy, with less of the post-meal glucose excursion and downstream fat storage seen in metabolically dysregulated patients. What this means for your specific diet is a consultation conversation, not a public recommendation. The Phase 2 and Phase 3 trials tested fixed-dose retatrutide versus placebo - they did not randomize patients to specific macronutrient patterns, so we do not have RCT-grade evidence for an "optimal" diet on retatrutide. Common-sense guidance applies and is reflected in the Lifestyle section above: protein-forward for lean-mass preservation, moderate caloric deficit (not extreme), clean carbs over refined ones, electrolytes during titration. Most importantly: with rapid weight loss, lean mass preservation is the variable that determines whether your metabolic improvement is durable post-cycle, and that depends on protein intake and resistance training, not carb timing.

What about ketogenic or carnivore diets while on retatrutide?

Carb restriction has a theoretical interaction with retatrutide's glucagon-receptor activity that has not been well-characterised in trial populations - the concern is altered ketogenesis and theoretical diabetic ketoacidosis risk in susceptible patients. Many users self-report doing keto or carnivore on retatrutide without obvious issue, but the absence of trial data means Vivre cannot recommend it as a default. If carb restriction is part of your protocol, regular blood ketone monitoring becomes mandatory and your physician needs visibility on the pattern. Standard Vivre guidance is a moderate caloric deficit with adequate protein, micronutrient-dense food, and ample fibre - not aggressive carb restriction.

How long does a reconstituted vial last, and why does Vivre use 10–20mg vials instead of larger ones?

Once reconstituted with bacteriostatic water and refrigerated at 2–8°C, retatrutide remains at acceptable potency for approximately 4 weeks. Beyond that, measurable degradation accumulates - aggregation, oxidation, and conformational drift (α-helix → random coil) are the mechanisms. Every additional day in solution is degradation, even at proper refrigeration. Vivre sources retatrutide in 10–20mg vials specifically to match a real 2–4 week consumption window per vial. This means the dose you inject in week 3 is at near-peak potency. Larger 30–50mg vials sold by some research vendors only work at peak potency for the first 2–3 weeks of a 4–6 week consumption window - by the time you reach the final doses, dose-to-dose consistency has drifted. Standard handling: keep lyophilized vials refrigerated before reconstitution, refrigerate immediately after mixing, never freeze a reconstituted vial, protect from direct light, and warm only briefly to room temperature before injection. The trade-off Vivre accepts is more frequent shipments and reconstitutions - in exchange for predictable dose-to-dose response.

✚

Patient Bloodwork Guide

Bloodwork for Metabolic & Weight Protocols

GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2

These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.

Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.

Blood sugar & insulin

Fasting insulinTracks insulin sensitivity - usually the first thing to improve.

HbA1cYour 3-month average blood sugar.

Fasting glucoseRoutine blood-sugar tracking.

Heart & lipids

Full lipid panelLDL, HDL, triglycerides, ApoB - these shift meaningfully during weight loss.

Resting heart rate & BPSimple checks tracked through the protocol.

Muscle & body composition

IGF-1Helps your physician protect lean mass during rapid weight loss.

DEXA / body compositionConfirms you are losing fat, not muscle - the goal of pairing with resistance training.

Overall safety

CMP & liver enzymesKidney and liver function (AST/ALT), watched especially when compounds are combined.

ThyroidBaseline check, as thyroid influences metabolic rate.

When the tests happen

BaselineCMP, HbA1c, fasting insulin, full lipids, liver, thyroid, IGF-1, DEXA.

Weeks 4 / 8 / 12 / 16Weight, resting HR, BP, symptom check.

QuarterlyCMP, HbA1c, fasting insulin, lipids, liver, IGF-1, body composition.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

◷

Lean-Mass Support During Weight Loss

A related option - discuss with your physician

Rapid GLP-1/GIP weight loss reduces fat and lean muscle. The foundation for preserving muscle is resistance training and adequate protein (roughly 1.2–1.6 g/kg/day for most people losing weight) - these do most of the work and come first.

As an adjunct, some patients discuss a GH-axis secretagogue protocol with their physician, on the rationale that supporting the growth-hormone / IGF-1 axis may help protect lean mass during a caloric deficit. This is mechanistically reasonable but not established by combination-outcome trials - there is no study showing it preserves more muscle than training and protein alone. Whether it is appropriate is a physician decision.

Educational only - not a recommendation to combine compounds or a dosing instruction. Any protocol decision is made by your supervising physician.

⊞

Technical Profile

Measurable Properties

Class	Triple receptor agonist - GLP-1 / GIP / glucagon
Receptor potency (EC50)	GIPR ~0.06 nM · GLP-1R ~0.78 nM · GCGR ~5.8 nM
Terminal half-life	~6 days - supports once-weekly physician-directed dosing
Metabolism	Primarily hepatic; minimal cytochrome P450 interaction
Evidence base	Investigational - late-stage trials; not yet an approved therapy
Regulatory status	Investigational - physician-supervised allocation only, with informed consent

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Investigational agent. Mechanistic/PK values from trial literature. Educational only; not a dosing instruction. Dose, frequency and suitability are physician-determined.

Clinical Literature

Peer-Reviewed References

Triple–Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023 · New England Journal of Medicine 2023;389:514–526

▾

Findings

Phase 2 randomized controlled trial in 338 adults with obesity. At the 12 mg dose, mean weight reduction was approximately 24.2% over 48 weeks versus ~2% in the placebo group. Gastrointestinal adverse events were dose-related, predominantly mild-to-moderate. The study established proof-of-concept for triple GLP-1/GIP/glucagon receptor activation; Retatrutide remains investigational and not an approved therapy.

View on publisher ↗

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial

Rosenstock J, Frías JP, Jastreboff AM, et al. · 2023 · The Lancet 2023;402:529–544

▾

Findings

Phase 2 trial in 281 adults with type 2 diabetes. At the 12 mg dose, mean body-weight reduction was approximately 16.9% at 24 weeks, with clinically meaningful improvements in HbA1c. Magnitude of weight reduction was notable given that weight loss in type 2 diabetes has historically been harder to achieve than in obesity alone. Results supported progression to the Phase 3 TRIUMPH programme.

View on publisher ↗

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized phase 2a trial

Sanyal AJ, Kaplan LM, Frías JP, et al. · 2024 · Nature Medicine 2024

▾

Findings

Phase 2a sub-study in adults with MASLD. The 12 mg dose produced reductions in liver fat content of approximately 82–86% with a high proportion of participants achieving normalisation of liver fat. Effects were dose-dependent. Findings positioned Retatrutide as a candidate for MASLD/MASH indications, now under further Phase 3 investigation.

View on publisher ↗

Retatrutide is investigational. The Phase 2 data across obesity, type 2 diabetes, and MASLD indications are encouraging but do not constitute regulatory approval. The first Phase 3 readout from the TRIUMPH programme (TRIUMPH-4, December 2025) was announced via Eli Lilly press release - reporting up to 28.7% mean weight reduction at 68 weeks in adults with obesity and knee osteoarthritis - but the peer-reviewed publication is not yet available. Vivre does not cite press-release data at the same evidence weight as peer-reviewed trials. Further TRIUMPH Phase 3 readouts (T2D, cardiovascular outcomes, OSA, MASLD) are expected through 2026; FDA submission timeline indicated by the sponsor is Q4 2026 or Q1 2027. Allocation at Vivre is physician-supervised with informed consent that explicitly addresses investigational status.

◇

Clinical Applications

Indications

Obesity in patients refractory to GLP-1 monotherapy
Severe metabolic syndrome
Patients requiring greater weight reduction than achievable with current FDA-approved options

▲

Required Protocol

The drug is not the protocol - the protocol is the protocol

Resistance training 3×/week - non-negotiable. Rapid weight loss on triple-agonists strips lean muscle alongside fat; resistance training is what preserves it. Skipping this trades long-term metabolic health for a number on the scale.
Protein 1.5–2g per kg bodyweight daily - to protect lean mass during caloric deficit and support recovery from training.
Adjust eating habits for the long term - the medication suppresses appetite, but the goal is durable healthy patterns that hold after the protocol, not just during it.
The compound is an accelerant, not the intervention. Without the training, protein, and dietary changes, the result is muscle loss and rebound. Vivre dispenses the compound only as part of this full protocol, monitored by your physician.

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~6 days. Designed for once-weekly subcutaneous administration; the only investigational triple-agonist (GLP-1/GIP/glucagon) in late-stage development.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Phase 2 and Phase 3 trial data emerging. Not yet FDA-approved. Allocation requires individual physician case review.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including Retatrutide

◎

Commonly Paired

Compounds Often Prescribed With Retatrutide

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Growth Hormone Secretagogue

Tesamorelin

GHRH Analog · 10mg

◆ lean-mass preservation

Tesamorelin co-allocated for lean-mass preservation during aggressive multi-receptor metabolic intervention. This pairing appears in Vivre's V-M2 metabolic protocol.

View Tesamorelin detail →

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ GI tolerance

BPC-157 supports gastric tolerance during triple-agonist therapy, where GI burden is dose-dependent. Also part of V-M2.

View BPC-157 detail →

READY TO PROCEED

Start with the Biological Audit

Retatrutide is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$175 USD/vial

Retatrutide · Member rate